WO1996009314A3 - Method for loading solid supports for nucleic acid synthesis - Google Patents

Method for loading solid supports for nucleic acid synthesis Download PDF

Info

Publication number
WO1996009314A3
WO1996009314A3 PCT/US1995/012196 US9512196W WO9609314A3 WO 1996009314 A3 WO1996009314 A3 WO 1996009314A3 US 9512196 W US9512196 W US 9512196W WO 9609314 A3 WO9609314 A3 WO 9609314A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid supports
loading
nucleic acid
acid synthesis
hobt
Prior art date
Application number
PCT/US1995/012196
Other languages
French (fr)
Other versions
WO1996009314A2 (en
Inventor
Nandkumar Bhongle
Jin-Yan Tang
Original Assignee
Hybridon Inc
Nandkumar Bhongle
Tang Jin Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc, Nandkumar Bhongle, Tang Jin Yan filed Critical Hybridon Inc
Priority to AU37242/95A priority Critical patent/AU3724295A/en
Publication of WO1996009314A2 publication Critical patent/WO1996009314A2/en
Publication of WO1996009314A3 publication Critical patent/WO1996009314A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

New methods of loading solid supports for oligonucleotide synthesis are presented. The new methods comprise coupling a succinylated nucleoside to a solid support using diisopropylcarbodiimide (DIC) as an activator and N-hydroxybenzotriazole (HOBT) as an acid catalyst. DIC is substantially cheaper than the currently used activating agent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). Furthermore, in the preferred embodiment, when it is used in combination with HOBT, coupling is more efficient, requiring less nucleoside to achieve the same loading densities as in the prior art. The loading process is faster than prior art methods and the overall cost savings of about 43 % are realized.
PCT/US1995/012196 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis WO1996009314A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37242/95A AU3724295A (en) 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/311,156 US5554744A (en) 1994-09-23 1994-09-23 Method for loading solid supports for nucleic acid synthesis
US08/311,156 1994-09-23

Publications (2)

Publication Number Publication Date
WO1996009314A2 WO1996009314A2 (en) 1996-03-28
WO1996009314A3 true WO1996009314A3 (en) 1996-05-30

Family

ID=23205659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012196 WO1996009314A2 (en) 1994-09-23 1995-09-22 Method for loading solid supports for nucleic acid synthesis

Country Status (4)

Country Link
US (1) US5554744A (en)
AU (1) AU3724295A (en)
CA (1) CA2200552A1 (en)
WO (1) WO1996009314A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
EP1356088A2 (en) * 2000-06-07 2003-10-29 Baylor College of Medicine Compositions and methods for array-based nucleic acid hybridization
WO2003020978A1 (en) * 2001-09-01 2003-03-13 Samsung Electronics Co., Ltd. Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
JP2005519634A (en) * 2001-10-12 2005-07-07 スペクトラル ジェノミクス、インク． Nucleic acid compositions and arrays and methods using them
US7439346B2 (en) 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
WO2003042697A1 (en) * 2001-11-14 2003-05-22 Genospectra, Inc. Biochemical analysis system with combinatorial chemistry applications
US20030124542A1 (en) * 2001-12-28 2003-07-03 Spectral Genomics, Inc. Methods for mapping the chromosomal loci of genes expressed by a cell
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20050009051A1 (en) * 2002-09-27 2005-01-13 Board Of Regents, The University Of Texas Diagnosis of mould infection
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
CA2557841A1 (en) * 2004-02-27 2005-09-09 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
EP2471921A1 (en) 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
ES2345993T3 (en) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate METHOD FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC ADDRESSING.
EP2302054B1 (en) 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20090264635A1 (en) 2005-03-25 2009-10-22 Applera Corporation Methods and compositions for depleting abundant rna transcripts
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
BRPI0906429B1 (en) 2008-01-10 2021-08-03 Research Development Foundation METHOD OF IDENTIFYING AN E. CHAFFEENSIS INFECTION IN AN INDIVIDUAL, USE OF ONE OR MORE SYNTHETIC POLYPEPTIDE AND KIT
MX2010008168A (en) 2008-01-25 2011-02-24 P53 Inc P53 biomarkers.
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100047876A1 (en) * 2008-08-08 2010-02-25 President And Fellows Of Harvard College Hierarchical assembly of polynucleotides
AU2009313255B2 (en) 2008-11-07 2014-08-07 Research Development Foundation Compositions and methods for the inhibition of Cripto/GRP78 complex formation and signaling
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
WO2011008530A2 (en) 2009-06-29 2011-01-20 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
CA2771769C (en) 2009-08-28 2019-10-29 Research Development Foundation Urocortin 2 analogs and uses thereof
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
EP2515899B1 (en) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
WO2011099664A1 (en) 2010-02-12 2011-08-18 엠앤디(주) Probe for hpv genotype diagnosis and analysis method thereof
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011128886A1 (en) 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. A micro-rna for cancer diagnosis, prognosis and therapy
WO2011156588A1 (en) 2010-06-09 2011-12-15 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CA2814049C (en) 2010-10-08 2021-07-13 President And Fellows Of Harvard College High-throughput single cell barcoding
ES2629890T3 (en) 2010-11-17 2017-08-16 Interpace Diagnostics, Llc miRNA as biomarkers to distinguish between benign and malignant thyroid neoplasms
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2670849A1 (en) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US10501791B2 (en) 2011-10-14 2019-12-10 President And Fellows Of Harvard College Sequencing by structure assembly
WO2013063519A1 (en) 2011-10-26 2013-05-02 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
WO2013184754A2 (en) 2012-06-05 2013-12-12 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using dna origami probes
CN104662544B (en) 2012-07-19 2018-08-03 哈佛大学校长及研究员协会 The method for storing information using nucleic acid
EP2897633B1 (en) 2012-09-18 2020-01-01 UTI Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US20140100124A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US9476089B2 (en) 2012-10-18 2016-10-25 President And Fellows Of Harvard College Methods of making oligonucleotide probes
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
US10398661B2 (en) 2013-02-28 2019-09-03 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
EP2970909A4 (en) 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
BR112016007391A2 (en) 2013-10-03 2017-08-01 Oklahoma Med Res Found biomarkers of activity, intensity and acute phase of systemic lupus erythematosus disease
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN116585308A (en) 2018-05-25 2023-08-15 Arca生物制药有限公司 Methods and compositions relating to bucindolol treatment of atrial fibrillation
WO2022097157A2 (en) 2020-11-09 2022-05-12 1E Therapeutics, Ltd. Catalytic sequence based methods of treating or preventing bacterial infections
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
EP4320445A1 (en) 2021-04-08 2024-02-14 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline
WO2024015766A1 (en) 2022-07-12 2024-01-18 Topogene Inc. Scalable, submicron-resolution replication of dna arrays

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013080A1 (en) * 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) * 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support
WO1991013080A1 (en) * 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. GUZAEV ET AL.: "Synthesis of 3'-functionalized oligonucleotides on a single solid support", TETRAHEDR. LETT., vol. 34, pages 8169 - 72 *
E. PEDROSO ET AL.: "Predictable and reproducible yields in the anchoring of DMT-nucleoside-succinates to highly loaded aminoalkyl-polystyrene resins", NUCLEOSIDES, NUCLEOTIDES, vol. 12, pages 967 - 71 *
J.M. LAWLOR ET AL.: "The synthesis of oligonucleotide-polyamide conjugate molecules suitable as PCR primers", J. ORG. CHEM., vol. 58, pages 2223 - 31 *
N. BHONGLE AND J.Y. TANG: "A convenient and practical method for dervatization of solid supports for nucleic acid synthesis", SYNTH. COMMUN., vol. 25, no. 22, pages 3671 - 9 *

Also Published As

Publication number Publication date
WO1996009314A2 (en) 1996-03-28
AU3724295A (en) 1996-04-09
CA2200552A1 (en) 1996-03-28
US5554744A (en) 1996-09-10

Similar Documents

Publication Publication Date Title
WO1996009314A3 (en) Method for loading solid supports for nucleic acid synthesis
SG60064A1 (en) Catalyst and process for producing unsaturated aldehyde and unsaturated acid
AU1414397A (en) Process for preparing blends of poly(ethylene terephthalate) and poly(ethylene 2,6-naphthalenedicarboxylate)
AU2096097A (en) Nucleic acid molecules coding for debranching enzymes from maize
PL316387A1 (en) Metalocenic compounds, method of obtaining them and their application as catalysts in polymerisation of olefins
IL149846A0 (en) Method for obtaining nucleic acids from an evironment sample, resulting nucleic acids and use in synthesis of novel compounds
SG46156A1 (en) Fluid bed process for the acetoxylation of ethylene in the production of vinyl acetate
AU1731195A (en) Process for recovering catalyst supports
ID21457A (en) CATALYST, PROCESS FOR PRODUCING CATALYST AND PROCESS FOR MAKING VINYL ACETATE USING CATALYST
BR9809715A (en) Catalyst for production of vinyl acetate by reaction of ethylene, oxygen and acetic acid and process for the production of the same
AU2682495A (en) Novel transferase and amylase, process for producing the enzymes,use thereof, and gene coding for the same
PL317089A1 (en) Catalyst for use in oxychlorination of ethylene, method of obtaining such catalysts and oxychlorination process employing such catalysts
ID21462A (en) CATALYST, PROCESS FOR PRODUCING SUCH CATALYST AND THE PROCESS OF MAKING VINYL ACETATE USING SUCH CATALYST
AU3671700A (en) Plant activator, process for producing the same, activation method, activity promoter and method for applying the promoter
EP0641830A3 (en) Curable compositions containing an anaerobically inactive hydrosilation catalyst and method for preparing said compositions.
ZA200002739B (en) Process for carrying out catalytic multiphase reactions, in particular vinylations of carboxylic acids.
ZA9811287B (en) Catalyst and process for preparing vinyl acetate
WO1998050530A3 (en) Enzymatic nucleic acids: synthesis, selection and use
HUP9602571A3 (en) Reduction catalyst composition, uses thereof and process for producing aldehydes and aldehyde-derivatives
KR960702770A (en) Hydrogen isomerization of catalysts and heavy feeds based on precious metals and silica-alumina (NOBLE METAL-AND SILICA / ALUMINA-BASED CATALYST AND METHOD FOR THE HYDROISOMERISATION PROCESSING OF HEAVY FEEDSTOCKS)
AU1372895A (en) Catalyst support and process for its use
ZA996280B (en) A method of modifying and controlling catalyst selectivity in a Fischer-Tropsch process.
ZA200105694B (en) Process of paraffin isomerisation and heteropoly acids supported on inert supports as isomerisation catalysts.
AU6246901A (en) Catalyst for fluidised bed carbonation of biomass, method for obtaining same and uses thereof
SG98385A1 (en) Catalysts for methacrylic acid production and process for producing methacrylic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2200552

Country of ref document: CA

Ref country code: CA

Ref document number: 2200552

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 809026

Date of ref document: 19970714

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase